Trial Profile
Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Induction Followed by Autologous Stem Cell Transplantation, CRd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 Years Old
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms IFM CRd
- 07 Apr 2021 Status changed from active, no longer recruiting to completed, as per Results published in the Blood
- 07 Apr 2021 Primary endpoint has been met (rate of stringent complete response), as per Results published in the Blood
- 07 Apr 2021 Results published in the Blood